Adicet Bio closed at $3.10 on Nov 4, down 2.21%, within 0.0% of its 52-week closing low. Volume of 292.3K shares was 1.36× its 20-day average (above normal).
Split-adjusted performance: -50.4% over one month, -63.7% over six months, -73.5% over one year.
Short interest was 521.9K shares at the Oct 15 settlement, up 7.5% from the prior report (6.3% of float, 2.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ACETAdicet Bio | $3.10 | −2.21% | −63.7% | — | — | — | $29.0M | |
| BYSIBeyondSpring | $0.6790 | +9.34% | −56.2% | — | — | — | $27.9M | Compare |
| BCTXBriacell Therapeutics | $3.19 | +5.98% | −23.1% | — | — | — | $27.9M | Compare |
| FLNAFilana Therapeutics | $0.5720 | −3.75% | — | — | — | — | $27.6M | Compare |
| AARDAardvark Therapeutics | $1.26 | +2.44% | −78.6% | — | — | — | $27.6M | Compare |
| RNAZTransCode Therapeutics | $1.60 | +1.91% | −78.7% | — | — | — | $27.1M | Compare |
| IXHLIncannex Healthcare Limited | $2.49 | −0.60% | −49.3% | — | — | — | $31.2M | Compare |
| NXTCNextCure | $5.85 | −1.02% | −45.4% | — | — | — | $26.8M | Compare |
| ABVCABVC BioPharma | $1.00 | +1.51% | −9.1% | — | — | — | $26.7M | Compare |
No recent articles focused on Adicet Bio. 1 articles mention it in passing.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
